specializing in the development of novel small molecule antibiotic
scaffolds for multi-drug resistant (MDR) Gram-negative pathogens
to address the urgent and growing global threat of antibiotic
resistance. The company is applying a multi-target strategy to
generate a pipeline of effective antibiotics with inhibitory activity
against a wide range of biological targets in essential pathways of
Gram-negative bacterial cells and which are also predicted to
defeat known antibiotic resistance mechanisms.